Immune characterization of metastatic colorectal cancer patients post reovirus administration.

ABSTRACT:

Background

KRAS mutations are prevalent in 40-45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination with chemotherapy is examined in a phase 1 study of metastatic CRC. This study evaluates the nature of immune response by determining the cytokine expression pattern in peripheral circulation along with the distribution of antigen presenting cells (APCs) and activated T lymphocytes. Further the study evaluates the alterations in exosomal and cellular microRNA levels along with the effect of reovirus on leukocyte transcriptome.

Methods

Reovirus was administered as a 60-min intravenous infusion for 5 consecutive days every 28 days,

SUBMITTER: Parakrama R 

PROVIDER: S-EPMC7301987 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature